ArticleActa neurologica Belgica2026
LC3B as a potential serum biomarker for screening high-risk neuroblastoma patients.
Article in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionNeuroblastoma (NB) is the most common extracranial solid tumour in children, with low 5-year survival rates in high-risk cases. Identifying new tumour biomarkers is essential for risk stratification. This study investigated the potential of LC3B as a prognostic biomarker for high-risk NB.
methodsPeripheral blood, tissue samples, and clinical data were collected from 53 children with NB. The expression rates of 16 biomarker antibodies in peripheral blood mononuclear cells were analysed using flow cytometry. NB mRNA expression profiles and clinical data from 282 tissue samples were obtained from the Gene Expression Omnibus database (GSE49710). Multivariate logistic regression assessed factors influencing high-risk NB, and a receiver operating characteristic curve (ROC) was plotted.
resultsFlow cytometry revealed that LC3B expression in peripheral blood mononuclear cells was significantly lower in the high-risk group compared to the low-intermediate-risk groups (P < 0.05). Analysis of the Gene Expression Omnibus database indicated that LC3B mRNA was highly expressed in low- to intermediate-risk patients but weakly in high-risk patients (P < 0.01). ROC analysis showed that LC3B expression has prognostic value for high-risk NB [AUC = 0.684, 95% CI: (0.541, 0.827)], which improves when combined with neuron-specific enolase (NSE) [AUC = 0.789, 95% CI: (0.667, 0.911)]. The expression level of LC3B mRNA in tumour tissues provided the best prognostic model for high-risk NB [AUC = 0.855, 95% CI: (0.808, 0.903)].
conclusionLC3B may be a novel prognostic biomarker for screening high-risk patients with NB, and combined detection with NSE could enhance prognostic accuracy.
Indexed as
Identifiers
41528631What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.